Patents by Inventor Michael C. Holmes

Michael C. Holmes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for modulating PD1
    Patent number: 10046028
    Abstract: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: August 14, 2018
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Michael C. Holmes, Matthew C. Mendel, Xiangdong Meng, David Paschon, Andreas Reik, Fyodor Urnov
  • METHODS AND COMPOSITIONS FOR TREATMENT OF A GENETIC CONDITION
    Publication number: 20180223311
    Abstract: Methods and compositions for a genetic disease are provided.
    Type: Application
    Filed: April 2, 2018
    Publication date: August 9, 2018
    Inventors: Gregory J. Cost, Philip D. Gregory, Dmitry Guschin, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • DELIVERY METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED GENOME ENGINEERING
    Publication number: 20180216136
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a cell.
    Type: Application
    Filed: March 26, 2018
    Publication date: August 2, 2018
    Inventors: Michael C. Holmes, Jianbin Wang
  • TARGETED DISRUPTION OF T CELL RECEPTOR GENES USING ENGINEERED ZINC FINGER PROTEIN NUCLEASES
    Publication number: 20180214485
    Abstract: Disclosed herein are methods and compositions for modifying TCR genes, using nucleases (zinc finger nucleases or TAL nucleases) to modify TCR genes.
    Type: Application
    Filed: March 26, 2018
    Publication date: August 2, 2018
    Inventors: Philip D. Gregory, Michael C. Holmes, David Paschon, Lei Zhang, Maria Chiara Bonini, Pietro Genovese, Zulma Magnani, Sara Mastaglio, Luigi Naldini
  • DELIVERY OF TARGET SPECIFIC NUCLEASES
    Publication number: 20180185516
    Abstract: Described herein are lipid nanoparticles comprising cationic lipids and other lipids and also comprising engineered nucleases facilitate transfer of nucleic acids to cells.
    Type: Application
    Filed: December 8, 2017
    Publication date: July 5, 2018
    Inventors: Steven M. Ansell, Christopher Barbosa, Anthony Conway, Xinyao Du, Michael J. Hope, Michael C. Holmes, Gary K. Lee, Paulo Jia Ching Lin, Thomas Madden, Barbara Mui
  • Methods and compositions for treatment of a genetic condition
    Patent number: 9963715
    Abstract: Disclosed herein are nucleases and methods of using these nucleases for alteration of a globin gene and generation of cells.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: May 8, 2018
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Philip D. Gregory, Dmitry Guschin, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • Delivery methods and compositions for nuclease-mediated genome engineering
    Patent number: 9957526
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a cell.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: May 1, 2018
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Jianbin Wang
  • Targeted disruption of T cell receptor genes using talens
    Patent number: 9937207
    Abstract: Disclosed herein are methods and compositions for modifying TCR genes, using nucleases (zinc finger nucleases or TAL nucleases) to modify TCR genes.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: April 10, 2018
    Assignees: Sangamo Therapeutics, Inc., Ospedale San Raffaele SRL
    Inventors: Philip D. Gregory, Michael C. Holmes, David Paschon, Lei Zhang, Maria Chiara Bonini, Pietro Genovese, Zulma Magnani, Sara Mastaglio, Luigi Naldini
  • Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
    Patent number: 9833479
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted integration of a functional SCID-related genes (e.g., IL2RG, RAG1 and/or RAG2 gene) into the genome of a cell for provision of proteins lacking or deficient in SCID.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: December 5, 2017
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Gregory J. Cost, Michael C. Holmes, Fyodor Urnov
  • Targeted integration into stem cells
    Patent number: 9834787
    Abstract: Disclosed herein are methods and compositions for targeted integration of sequences of interest such as lineage-specific or cell fate reporter constructs or protein encoding sequences into stem cells.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: December 5, 2017
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Dirk Hockemeyer, Michael C. Holmes, Rudolf Jaenisch, Frank Soldner, Fyodor Urnov, Shuyuan Yao
  • METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION
    Publication number: 20170326174
    Abstract: Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.
    Type: Application
    Filed: June 30, 2017
    Publication date: November 16, 2017
    Inventors: Michael C. Holmes, Fyodor Urnov
  • Methods and compositions for targeted cleavage and recombination
    Patent number: 9782437
    Abstract: Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: October 10, 2017
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Fyodor Urnov
  • Linear donor constructs for targeted integration
    Patent number: 9765360
    Abstract: Disclosed herein are linear donor molecules comprising homology arms of 50-750 base pairs (e.g., 50-100 base pairs) flanking one or more sequences of interest. The donor molecules and/or compositions comprising these molecules can be used in methods for targeted integration of an exogenous sequence into a specified region of interest in the genome of a cell.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: September 19, 2017
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Russell DeKelver, Philip D. Gregory, Michael C. Holmes, Fyodor Urnov
  • Methods and compostions for targeted genomic deletion
    Patent number: 9752140
    Abstract: Disclosed herein are compositions and methods for generating chromosomal translocations and targeted deletions of specific lengths and at specific locations the genome of cell.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: September 5, 2017
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Fyodor Urnov, Jianbin Wang, Michael C. Holmes
  • Modification of CXCR4 using engineered zinc finger proteins
    Patent number: 9717759
    Abstract: Disclosed herein are methods and compositions for modulating activity of CXCR4 genes, for example using zinc finger transcription factors (ZF-TFs) or zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZF-TFs or ZFNs, vectors comprising polynucleotides encoding ZF-TFs or ZFNs and cells comprising polynucleotides encoding ZF-TFs or ZFNs and/or cells comprising ZF-TF or ZFNs are also provided.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: August 1, 2017
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Jeffrey C. Miller, Jianbin Wang
  • METHODS AND COMPOSITIONS FOR ENGINEERING IMMUNITY
    Publication number: 20170196992
    Abstract: Nucleases and methods of using these nucleases for expressing an antibody from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Application
    Filed: November 21, 2016
    Publication date: July 13, 2017
    Inventors: Michael C. Holmes, Brigit E. Riley
  • GENE CORRECTION OF SCID-RELATED GENES IN HEMATOPOIETIC STEM AND PROGENITOR CELLS
    Publication number: 20170189450
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted integration of a functional SCID-related genes (e.g., IL2RG, RAG1 and/or RAG2 gene) into the genome of a cell for provision of proteins lacking or deficient in SCID.
    Type: Application
    Filed: March 14, 2017
    Publication date: July 6, 2017
    Inventors: Anthony Conway, Gregory J. Cost, Michael C. Holmes, Fyodor Urnov
  • T CELL MODIFYING COMPOUNDS AND USES THEREOF
    Publication number: 20170183420
    Abstract: Methods and compositions for modifying T-cells in which PD1 and/or CTLA-4 is repressed and/or inactivated using fusion proteins such as artificial transcription factors and nucleases.
    Type: Application
    Filed: March 8, 2017
    Publication date: June 29, 2017
    Inventors: Philip D. Gregory, Michael C. Holmes
  • Methods and compositions for treatment of a genetic condition
    Patent number: 9650648
    Abstract: Methods and compositions for a genetic disease are provided.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: May 16, 2017
    Assignee: SANGAMO BIOSCIENCES, INC.
    Inventors: Gregory J. Cost, Philip D. Gregory, Dmitry Guschin, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • Methods and compositions for treating hemophilia B
    Patent number: 9629930
    Abstract: Disclosed herein are methods and compositions for insertion of Factor IX (FIX) sequences into the genome of a cell for treating hemophilia B.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 25, 2017
    Assignees: Sangamo Biosciences, Inc., The Children's Hospital of Philadelphia
    Inventors: Philip D. Gregory, Katherine A. High, Michael C. Holmes, Hojun Li